SCHEMBL661353

SCHEMBL661353

CC(CCCO)CCCCCC(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 5/20 0.60
FFAR1 O14842 3/20 0.60
FFAR4 Q5NUL3 3/20 0.60
CAMK2A Q9UQM7 1/20 0.52
TSHR P16473 5/20 0.50
LMNA P02545 1/20 0.50
NFKB1 P19838 1/20 0.50
PMP22 Q01453 1/20 0.50
ALDH1A1 P00352 3/20 0.48
GSTK1 Q9Y2Q3 1/20 0.47
PPARG P37231 6/20 0.46
PPARD Q03181 6/20 0.46
PPARA Q07869 6/20 0.46
HDAC11 Q96DB2 5/20 0.46
TLR2 O60603 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
FABP4 P15090 2/20 0.46
PTPN1 P18031 2/20 0.46
SLC22A6 Q4U2R8 1/20 0.46
SLC22A8 Q8TCC7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5168516 1.00 GPR84 (0.60) GPR84FFAR1FFAR4CAMK2ATSHR
SCHEMBL15798128 0.98 GPR84 (0.56) GPR84FFAR1FFAR4CAMK2ATSHR
SCHEMBL8984460 0.96 GPR84 (0.67) GPR84FFAR1FFAR4CAMK2ATSHR
SCHEMBL8984458 0.96 GPR84 (0.67) GPR84FFAR1FFAR4CAMK2ATSHR
SCHEMBL8984358 0.96 GPR84 (0.67) GPR84FFAR1FFAR4CAMK2ATSHR
SCHEMBL8044968 0.96 GPR84 (0.67) GPR84FFAR1FFAR4CAMK2ATSHR
SCHEMBL8984604 0.96 GPR84 (0.67) GPR84FFAR1FFAR4CAMK2ATSHR
SCHEMBL8984607 0.96 GPR84 (0.67) GPR84FFAR1FFAR4CAMK2ATSHR
SCHEMBL8984489 0.92 GPR84 (0.60) GPR84FFAR1FFAR4CAMK2ATSHR
SCHEMBL4478217 0.92 GPR84 (0.54) GPR84FFAR1FFAR4TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117860766-A Composition containing ether type glycerophospholipids and method for producing same 物心科技株式会社 2024-04-12 CN disclosed
US-11345690-B2 Methods of synthesizing a difluorolactam analog CAYMAN CHEMICAL COMPANY, INC. (US) 2022-05-31 US disclosed
US-20220127252-A9 METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG CAYMAN CHEMICAL CO INC (US) 2022-04-28 US disclosed
US-20190202816-A1 METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG CAYMAN CHEMICAL CO INC (US) 2019-07-04 US disclosed
US-20190167799-A1 ETHER TYPE GLYCEROPHOSPHOLIPID-CONTAINING COMPOSITION AND METHOD FOR PRODUCING THE SAME B&S CORPORATION:KK (JP) 2019-06-06 US disclosed
US-20190133986-A1 METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION UNIVERSITY OF WASHINGTON 2019-05-09 US disclosed
EP-2252276-B1 METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION UNIV WASHINGTON (US) 2019-03-27 EP disclosed
US-20180170918-A1 METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG CAYMAN CHEMICAL CO INC (US) 2018-06-21 US disclosed
US-20180098955-A1 METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION UNIVERSITY OF WASHINGTON 2018-04-12 US disclosed
US-9914725-B2 Methods of synthesizing a difluorolactam analog CAYMAN CHEMICAL COMPANY, INC. (US) 2018-03-13 US disclosed
US-20030158246-A1 For the treatment of prostaglandin mediated diseases, such as allergic asthma or rhinitis. MERCK FROSST CANADA & CO. (CA) 2003-08-21 US disclosed
WO-2003062200-A2 FLUORO SUBSTITUTED CYCLOALKANOINDOLES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS MERCK FROSST CANADA & CO. (CA) 2003-07-31 WO disclosed
EP-1305286-A2 CYCLOPENTANOINDOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK FROSST CANADA INC. (CA) 2003-05-02 EP disclosed
US-6410583-B1 PROSTAGLANDIN ANTAGONIST MERCK FROSST CANADA & CO. (CA) 2002-06-25 US disclosed
WO-2002008186-A2 CYCLOPENTANOINDOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK FROSST CANADA & CO. (CA) 2002-01-31 WO disclosed
EP-0826684-B1 PIPERIDINE DERIVATIVES HISAMITSU PHARMACEUTICAL CO (JP) 2001-11-21 EP disclosed
US-5886011-A TACHYKININ UNDECAPEPTIDE ANTAGONIST, USEFUL FOR TREATING ASTHMA, OR REMEDY FOR DISEASES ASSOCIATED WITH CENTRAL NERVOUS SYSTEM, DIGESTIVE SYSTEM AND CIRULATORY STYSTEM, AND VARIETY OF PAINS OR INFLAMMATION HISAMITSU PHARMACEUTICAL CO., INC. (JP) 1999-03-23 US disclosed
EP-0826684-A1 PIPERIDINE DERIVATIVES Hisamitsu Pharmaceutical Co., Inc. (JP) 1998-03-04 EP disclosed
US-5621140-A Resolution of ibuprofen SYNTEX (U.S.A.) INC. (US) 1997-04-15 US disclosed
WO-1996019431-A1 RESOLUTION OF IBUPROFEN USING A N-ALKYL-D-GLUCAMINE F. HOFFMANN-LA ROCHE AG (CH) 1996-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190167799-A1 ETHER TYPE GLYCEROPHOSPHOLIPID-CONTAINING COMPOSITION AND METHOD FOR PRODUCING THE SAME PHOSPHO1, DDOST, CDIPT GPR84 2609/4885FFAR1 2993/4885FFAR4 2343/4885
US-20030158246-A1 For the treatment of prostaglandin mediated diseases, such as allergic asthma or rhinitis. PTGES, PTGIR, PTGER1 GPR84 190/4885FFAR1 108/4885FFAR4 117/4885
US-20190133986-A1 METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION ALDH1A2, ALDH1A3, RBP4 GPR84 604/4885FFAR1 358/4885FFAR4 628/4885
US-20190202816-A1 METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG PTGER4, PTGER1, PTGIR GPR84 21/4885FFAR1 60/4885FFAR4 17/4885
US-11345690-B2 Methods of synthesizing a difluorolactam analog PTGER4, PTGER1, PTGIR GPR84 21/4885FFAR1 60/4885FFAR4 17/4885
US-20180098955-A1 METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION ALDH1A2, ALDH1A3, RBP4 GPR84 604/4885FFAR1 358/4885FFAR4 628/4885
US-20180170918-A1 METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG PTGER4, PTGER1, PTGIR GPR84 21/4885FFAR1 60/4885FFAR4 17/4885
US-20220127252-A9 METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG PTGER4, PTGER1, PTGIR GPR84 21/4885FFAR1 60/4885FFAR4 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.